Ethnicity, body size, and estrogen levels in postmenopausal hispanic and non-hispanic white women

Journal of Women's Health

Volumn 18, Issue 4, 2009, Pages 487-491

  Wacker, Michael ^a   Risendal, Betsy ^b   Westerlind, Kim ^c   Lezotte, Dennis ^c   Byers, Tim ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Global Health and Health Disparities   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; ESTRADIOL;

ADULT; AGED; ARTICLE; BODY MASS; BODY SIZE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; ETHNICITY; EUROPEAN AMERICAN; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL;

AGED; BODY SIZE; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HISPANIC AMERICANS; HUMANS; HYDROXYESTRONES; MIDDLE AGED; POSTMENOPAUSE; RISK;

EID: 64749100335     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2008.0835     Document Type: Article

References (14)

1. Chebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: Factors influencing differences in incidence and outcome. J Natl Cancer Inst 2005;97:439-448.
2. McTiernan A, Rajan KB, Tworoger SS, et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 2003;21:1961-1966.
3. Modugno F, Kip KE, Cochrane B, et al. Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. Int J Cancer 2006;118:1292-1301.
4. Slattery ML, Sweeney C, Edwards S, et al. Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. Breast Cancer Res Treat 2007;102:85-101.
5. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-616.
6. Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 2002;287:216- 220.
7. Adly L, Hill D, Sherman ME, et al. Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women. Int J Cancer 2006;119:2402-2407.
8. Jernstrom H, Klug TL, Sepkovic DW, Bradlow HL, Narod SA. Predictors of the plasma ratio of 2-hydroxyestrone to 16a-hydroxyestrone among premenopausal, nulliparous women from four ethnic groups. Carcinogenesis 2003;24: 991-1005.
9. Setiawan VW, Haiman CA, Stanczyk FZ, Le Marchand L, Henderson BE. Racial/ethnic differences in postmenopausal endogenous hormones: The Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev 2006;15:1849-1855.
10. Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: A case-control study. Cancer Epidemiol Biomarkers Prev 1997;6:505-509.
11. Ursin G, London S, Stanczyk FZ, et al. Urinary 2-hydroxyestrone/16a- hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999; 91:1067-1072.
12. Meilahn EN, De Stavola B, Allen DS, et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III Cohort Follow-up. Br J Cancer 1998;78:1250-1255.
13. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: A prospective study of the 2:16α-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000;11:635-640.
14. Cauley JA, Zmuda JM, Danielson ME, et al. Estrogen metabolites and the risk of breast cancer in older women. Epidemiology 2003;14:740-744.